BRPI0512422A - compostos e composições como inobidores da proteìna quinase - Google Patents
compostos e composições como inobidores da proteìna quinaseInfo
- Publication number
- BRPI0512422A BRPI0512422A BRPI0512422-0A BRPI0512422A BRPI0512422A BR PI0512422 A BRPI0512422 A BR PI0512422A BR PI0512422 A BRPI0512422 A BR PI0512422A BR PI0512422 A BRPI0512422 A BR PI0512422A
- Authority
- BR
- Brazil
- Prior art keywords
- compounds
- compositions
- protein kinase
- kinase inhibitors
- sapk2
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 239000003909 protein kinase inhibitor Substances 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 101100457333 Homo sapiens MAPK11 gene Proteins 0.000 abstract 2
- 108700036166 Mitogen-Activated Protein Kinase 11 Proteins 0.000 abstract 2
- 102100026929 Mitogen-activated protein kinase 11 Human genes 0.000 abstract 2
- 101150046814 SAPK2 gene Proteins 0.000 abstract 2
- 230000002159 abnormal effect Effects 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 abstract 1
- 102100023274 Dual specificity mitogen-activated protein kinase kinase 4 Human genes 0.000 abstract 1
- 102100023401 Dual specificity mitogen-activated protein kinase kinase 6 Human genes 0.000 abstract 1
- 101150036586 FES gene Proteins 0.000 abstract 1
- 102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 abstract 1
- 101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 abstract 1
- 108060006662 GSK3 Proteins 0.000 abstract 1
- 102000001267 GSK3 Human genes 0.000 abstract 1
- 101001115395 Homo sapiens Dual specificity mitogen-activated protein kinase kinase 4 Proteins 0.000 abstract 1
- 101000624426 Homo sapiens Dual specificity mitogen-activated protein kinase kinase 6 Proteins 0.000 abstract 1
- 101000950695 Homo sapiens Mitogen-activated protein kinase 8 Proteins 0.000 abstract 1
- 101000950669 Homo sapiens Mitogen-activated protein kinase 9 Proteins 0.000 abstract 1
- 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 abstract 1
- 101000922131 Homo sapiens Tyrosine-protein kinase CSK Proteins 0.000 abstract 1
- 102100037808 Mitogen-activated protein kinase 8 Human genes 0.000 abstract 1
- 102100037809 Mitogen-activated protein kinase 9 Human genes 0.000 abstract 1
- 101100335081 Mus musculus Flt3 gene Proteins 0.000 abstract 1
- 101150056950 Ntrk2 gene Proteins 0.000 abstract 1
- 108091000080 Phosphotransferase Proteins 0.000 abstract 1
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 abstract 1
- 101001045447 Synechocystis sp. (strain PCC 6803 / Kazusa) Sensor histidine kinase Hik2 Proteins 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 230000006806 disease prevention Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- NFVJNJQRWPQVOA-UHFFFAOYSA-N n-[2-chloro-5-(trifluoromethyl)phenyl]-2-[3-(4-ethyl-5-ethylsulfanyl-1,2,4-triazol-3-yl)piperidin-1-yl]acetamide Chemical compound CCN1C(SCC)=NN=C1C1CN(CC(=O)NC=2C(=CC=C(C=2)C(F)(F)F)Cl)CCC1 NFVJNJQRWPQVOA-UHFFFAOYSA-N 0.000 abstract 1
- -1 p70S6K Proteins 0.000 abstract 1
- 239000008194 pharmaceutical composition Chemical class 0.000 abstract 1
- 102000020233 phosphotransferase Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Transplantation (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US58246704P | 2004-06-23 | 2004-06-23 | |
| US58856304P | 2004-07-15 | 2004-07-15 | |
| PCT/US2005/022463 WO2006002367A1 (en) | 2004-06-23 | 2005-06-23 | Compounds and compositions as protein kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0512422A true BRPI0512422A (pt) | 2008-03-04 |
Family
ID=35782143
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0512422-0A BRPI0512422A (pt) | 2004-06-23 | 2005-06-23 | compostos e composições como inobidores da proteìna quinase |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US7423038B2 (enExample) |
| EP (1) | EP1765820A4 (enExample) |
| JP (1) | JP2008504281A (enExample) |
| AU (1) | AU2005258266A1 (enExample) |
| BR (1) | BRPI0512422A (enExample) |
| CA (1) | CA2570494A1 (enExample) |
| MX (1) | MXPA06015147A (enExample) |
| RU (1) | RU2007102226A (enExample) |
| WO (1) | WO2006002367A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8119655B2 (en) | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| SG158147A1 (en) | 2006-10-09 | 2010-01-29 | Takeda Pharmaceutical | Kinase inhibitors |
| US8216783B2 (en) * | 2008-04-14 | 2012-07-10 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Over-expression and mutation of a tyrosine kinase receptor FGFR4 in tumors |
| US9273077B2 (en) | 2008-05-21 | 2016-03-01 | Ariad Pharmaceuticals, Inc. | Phosphorus derivatives as kinase inhibitors |
| EP2300013B2 (en) | 2008-05-21 | 2024-11-13 | Takeda Pharmaceutical Company Limited | Phosphorous derivatives as kinase inhibitors |
| WO2010022169A1 (en) * | 2008-08-19 | 2010-02-25 | Cedars-Sinai Medical Center | Methods of inhibiting fgfr3 signaling |
| EP2704572B1 (en) | 2011-05-04 | 2015-12-30 | Ariad Pharmaceuticals, Inc. | Compounds for inhibiting cell proliferation in egfr-driven cancers |
| WO2013071217A1 (en) * | 2011-11-10 | 2013-05-16 | OSI Pharmaceuticals, LLC | Dihydropteridinones |
| JP6469567B2 (ja) | 2012-05-05 | 2019-02-13 | アリアド・ファーマシューティカルズ・インコーポレイテッド | Ｅｇｆｒ発動性がんの細胞増殖阻害用化合物 |
| US9611283B1 (en) | 2013-04-10 | 2017-04-04 | Ariad Pharmaceuticals, Inc. | Methods for inhibiting cell proliferation in ALK-driven cancers |
| CN106279173A (zh) * | 2015-05-29 | 2017-01-04 | 华东理工大学 | 蝶啶酮衍生物作为egfr抑制剂的应用 |
| TWI831829B (zh) | 2018-09-12 | 2024-02-11 | 美商建南德克公司 | 苯氧基-吡啶基-嘧啶化合物及使用方法 |
| JP7539892B2 (ja) * | 2019-01-03 | 2024-08-26 | ジェネンテック， インコーポレイテッド | 癌疾患の処置のためのエンドリボヌクレアーゼのイノシトール要求酵素ｉ（ｉｒｅｉアルファ）の阻害剤としてのピリド－ピリミジノン化合物及びプテリジノン化合物 |
| JP2023549540A (ja) | 2020-11-18 | 2023-11-27 | デシフェラ・ファーマシューティカルズ，エルエルシー | Ｇｃｎ２およびｐｅｒｋキナーゼ阻害剤およびその使用方法 |
| CN115850282A (zh) * | 2021-09-24 | 2023-03-28 | 华东理工大学 | 靶向降解egfr蛋白的化合物及其制备方法和应用 |
| PE20250609A1 (es) | 2021-12-03 | 2025-02-26 | Deciphera Pharmaceuticals Llc | Inhibidores de gcn2 y perk quinasa y metodos de uso de los mismos |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7276506B2 (en) * | 1998-12-28 | 2007-10-02 | 4 Aza Bioscience Nv | Immunosuppressive effects of pteridine derivatives |
| KR20020027649A (ko) * | 1999-09-15 | 2002-04-13 | 로즈 암스트롱, 크리스틴 에이. 트러트웨인 | 카이나제 억제제로서의 프테리딘온 |
-
2005
- 2005-06-23 CA CA002570494A patent/CA2570494A1/en not_active Abandoned
- 2005-06-23 AU AU2005258266A patent/AU2005258266A1/en not_active Abandoned
- 2005-06-23 WO PCT/US2005/022463 patent/WO2006002367A1/en not_active Ceased
- 2005-06-23 MX MXPA06015147A patent/MXPA06015147A/es active IP Right Grant
- 2005-06-23 EP EP05763510A patent/EP1765820A4/en not_active Withdrawn
- 2005-06-23 JP JP2007518308A patent/JP2008504281A/ja active Pending
- 2005-06-23 RU RU2007102226/04A patent/RU2007102226A/ru not_active Application Discontinuation
- 2005-06-23 BR BRPI0512422-0A patent/BRPI0512422A/pt not_active IP Right Cessation
- 2005-06-23 US US11/570,661 patent/US7423038B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| WO2006002367A1 (en) | 2006-01-05 |
| MXPA06015147A (es) | 2007-03-26 |
| US7423038B2 (en) | 2008-09-09 |
| JP2008504281A (ja) | 2008-02-14 |
| AU2005258266A1 (en) | 2006-01-05 |
| CA2570494A1 (en) | 2006-01-05 |
| US20080113986A1 (en) | 2008-05-15 |
| RU2007102226A (ru) | 2008-07-27 |
| EP1765820A4 (en) | 2010-07-21 |
| EP1765820A1 (en) | 2007-03-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2008001969A (es) | Compuestos y composiciones como inhibidores de proteina cinasa. | |
| WO2006124731A3 (en) | Compounds and compositions as protein kinase inhibitors | |
| BRPI0511978A (pt) | compostos e composições como inibidores de proteìnas quinases | |
| BRPI0607307A2 (pt) | compostos e composições como inibidores de proteìna cinase | |
| BRPI0415210A (pt) | compostos e composições como inibidores de proteìna cinase | |
| WO2006124462A3 (en) | Compounds and compositions as protein kinase inhibitors | |
| TW200631577A (en) | Compounds and compositions as protein kinase inhibitors | |
| WO2006101783A3 (en) | Compounds and compositions as protein kinase inhibitors | |
| TNSN06053A1 (en) | 6-substituted anilino purines as rtk inhibitors | |
| BRPI0815572A2 (pt) | Compostos e composições como inibidores de quinases | |
| WO2008045627A3 (en) | Protein kinase inhibitors and methods for using thereof | |
| NI200900061A (es) | Composiciones y métodos para la modulación de los receptores c-kit y pdgf. | |
| BRPI0414049A (pt) | compostos e composições como inibidores de proteìna cinase | |
| PL2027123T3 (pl) | Związki i kompozycje jako inhibitory kinaz białkowych | |
| BRPI0507668A (pt) | compostos e composições como inibidores de proteìna cinase | |
| UA98629C2 (ru) | Соединения и способ модуляции киназ | |
| BRPI0414930A (pt) | compostos e composições como inibidores de proteìnas cinases | |
| PL1896470T3 (pl) | Pochodne pirolopirydynowe jako inhibitory kinazy białkowej | |
| PL1940844T3 (pl) | Związki i kompozycje jako inhibitory kinazy białkowej | |
| ECSP10010044A (es) | Compuestos de 5-(4-(halo-alcoxi)-fenil)-pirimidin-2-amina y composiciones como inhibidores de cinasa | |
| BRPI0413005A (pt) | compostos e composições como inibidores da proteìna cinase | |
| NO20092612L (no) | Forbindelser og metode for kinasemodulering og indikasjoner for dette | |
| MX2008001605A (es) | Compuestos y composiciones de tiazol-2-il amino 5-substituido como inhibidores de cinasa proteica. | |
| BRPI0414869A (pt) | compostos e composições como inibidores da proteìna quinase | |
| TH98294A (th) | องค์ประกอบและวิธีการสำหรับการปรับคุม C-kit รีเซปเตอร์ |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 6A E 7A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012. |